I n atherosclerosis, low-density lipoprotein (LDL) accumulates within the arterial wall, attracting immune cells and leading to chronic inflammation. 1 This process involves an autoimmune response to the protein moiety of LDL, apolipoprotein B100 (ApoB100). [2] [3] [4] [5] Antigen-presenting dendritic cells (DCs) traverse the arterial wall and the atherosclerotic plaque, where they may take up LDL components before migrating to lymphoid organs. This could initiate and boost cellular immune responses by presenting ApoB100 to T cells in the draining lymph nodes. 6 -10 Such responses contribute significantly to the progression of atherosclerosis. [11] [12] [13] 
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The evolving plaque is dominated by a T-helper 1 (Th1)type response, with production of proinflammatory cytokines such as interferon-␥ (IFN-␥), tumor necrosis factor (TNF-␣), and interleukin (IL)-12, 14 but also chemokines such as CCL2, CCL5, and CXCL4, 15 which stimulate the influx of various types of leukocytes. 16, 17 Several therapeutic strategies have been devised to dampen the inflammatory process in the plaque, but the limited mechanistic understanding of molecular mechanisms has hampered their translation into clinical utility. 2 However, advances in understanding the plasticity of the DC system may open up novel possibilities for the treatment of atherosclerosis.
DCs orchestrate the defense against infectious agents, as well as the maintenance and regulation of peripheral tolerance. 18, 19 Although immunogenic myeloid DCs play a major role in the initiation of inflammation and regulation of adaptive immunity, the tolerogenic properties of such DCs can be manipulated by immunomodulatory mediators such as cytokines, which provides opportunities for prevention and therapy of autoimmune diseases. 20, 21 Numerous approaches have been adopted during recent years to generate tolerogenic DCs for treatment of autoimmune disorders and improvement of allograft survival. 21 One of the most promising strategies includes induction of antigen-specific tolerogenic DCs by incubation with the immunosuppressive cytokine IL-10. Treatment of DCs with IL-10 downregulates secretion of inflammatory cytokines such as TNF-␣, IL-6, and IL-12; induces anergy of antigen-specific T cells; and promotes generation of regulatory T cells (Treg). [21] [22] [23] [24] [25] [26] [27] The utility of these immunoregulatory DCs as treatment of atherosclerotic disease has not been examined previously.
Here, we show that IL-10 imposes a regulatory phenotype on DCs, and that such tolerogenic DCs induce T-cell tolerance to ApoB100, blunt Th1 responses, and suppress autoimmune inflammation in hypercholesterolemic mice in an ApoB100-specific manner. Treatment of disease-prone hypercholesterolemic mice with a single injection of tolerogenic DCs led to significantly reduced atherosclerosis.
Methods
For an expanded Methods section, please refer to the online-only Data Supplement.
Preparation of ApoB100
LDL was isolated by ultracentrifugation from pooled plasma of healthy donors, as described previously, 28 and kept in a native state. ApoB100 was isolated by previously described methods. 5, 29, 30 ApoB100 preparations were more than 90% pure, as evaluated by gel-filtration high-performance liquid chromatography (GE Healthcare, Uppsala, Sweden).
Isolation and Loading of DCs
Myeloid DCs were generated as described previously. 31, 32 Briefly, bone marrow was isolated from huB100 tg ϫLdlr Ϫ/Ϫ mice (mice transgenic for human ApoB100 crossed with mice that were deficient for the LDL receptor). Bone marrow cells were depleted of red blood cells and cultured for 8 days in tissue culture dishes at 37°C and 7.5% CO 2 . DMEM culture medium was supplemented with 10% FCS, penicillin 50 U/mL, streptomycin 50 g/mL, L-glutamine 2 mmol/L, sodium pyruvate 1 mmol/L, granulocyte-macrophage colony-stimulating factor 10 ng/mL (Peprotech, Rocky Hill, NJ), and IL-4 10 ng/mL (Peprotech). Purification of DCs from the differentiated bone marrow cells was performed with a CD11c magnetic cell-sorting kit (Miltenyi Biotech, Göteborg, Sweden) according to the manufacturer's instructions.
For cell-transfer experiments, the purified DCs were incubated in tissue culture dishes with IL-10 (30 ng/mL), with or without ApoB100 (100 g/mL), in serum-free DMEM containing 1:100 BD ITS ϩ Premix (BD Biosciences, Franklin Lakes, NJ), BSA 1 mg/mL (Sigma-Aldrich, St Louis, MO), HEPES 10 mmol/L (Gibco Invitrogen, Carlsbad, CA), sodium pyruvate 1 mmol/L (Gibco Invitrogen), nonessential amino acids 1 mmol/L (Sigma-Aldrich), and gentamicin sulfate 50 g/mL (Sigma-Aldrich) at 37°C in a humid 5% CO 2 atmosphere. Four hours later, lipopolysaccharide (0.1 ng/mL; titrated to start DC maturation) was added. After another 14 hours, the cells were washed in DMEM, kept on ice, and injected into recipients within 1 hour. For measurement of cytokine release into the supernatant, the purified DCs were pulsed in 96-well plates (4ϫ10 5 cells per well).
Animal Experiments and Evaluation of Disease
Eleven-week-old male huB100 tg ϫLdlr Ϫ/Ϫ mice (C57BL/6129-ApoB tm2Sgy Ldlr tm1Her mice, 33, 34 kindly provided by Dr Jan Borén, Göteborg University), were injected intravenously with 2.5ϫ10 5 DCs pulsed with antigen and/or cytokine. The mice were fed a high-fat diet (0.15% cholesterol R638, Lantmännen, Malmö, Sweden) for 10 weeks starting 5 days after cell therapy. In some experiments, the mice were also immunized subcutaneously with 100 g of ApoB100 emulsified with complete Freund's adjuvant 1 week after DC injection. All experiments were approved by the local ethics committee.
Mice were euthanized under CO 2 anesthesia, blood was collected by cardiac puncture, and the vasculature was perfused with sterile RNase-free PBS. The descending thoracic aorta was dissected and fixed in 4% formaldehyde, opened longitudinally, pinned onto black wax plates, and stained with Sudan IV (Merck AG, Darmstadt, Germany). Lesion area and total aortic area were calculated with ImageJ software (National Institutes of Health, Bethesda, MD). Part of the spleen was used for cell experiments and snap-frozen for RNA isolation. Inguinal lymph nodes and abdominal aortas were snapfrozen and used for RNA isolation. Immunohistochemistry was performed on acetone-fixed cryosections from the aortic root of dissected mouse hearts as described previously. 35 
In Vitro Cell Culture Assay
Splenocytes from treated mice were isolated and resuspended in 96-well plates. A total of 5ϫ10 5 splenocytes were incubated with or without ApoB100 antigen in 200 L of DMEM supplemented with 2.5% mouse serum, penicillin 50 U/mL, streptomycin 50 g/mL, L-glutamine 2 mmol/L, and sodium pyruvate 1 mmol/L for 72 hours at 37°C in a humid 5% CO 2 atmosphere. One Ci of 3 H-thymidine (Sigma-Aldrich) was added after 60 hours, and DNA replication was measured with a scintillation counter (Wallac, Turku, Finland). Cytokines secreted in the cell culture supernatants after 72 hours were measured with an enzyme-linked immunosorbent assay kit (Mabtech, Nacka Strand, Sweden) or with a cytometric bead array flex set kit (BD Biosciences).
Flow Cytometry and Intracellular Cytokine Staining
To measure surface-marker expression, single-cell suspensions were prepared and stained with primary labeled antibodies (BD Biosciences) according to the manufacturer's instructions. For further characterization of cytokine profiles, 1ϫ10 4 CD4 ϩ T cells were incubated for 96 hours with 4ϫ10 4 DCs treated with or without IL-10 in the presence of anti-CD3 (2 g/mL) and restimulated for the last 4 hours of culture at 37°C in 7.5% CO 2 with phorbol 12-myristate 13-acetate (50 ng/mL), ionomycin (1 g/mL; Sigma), and GolgiPlug (1 L per 1 mL; BD Biosciences). All cells were incubated with Fc␥R block (BD Biosciences) followed by surface staining for CD4 and intracellular staining for IFN-␥, IL-10 (BD Biosciences), or FoxP3 (forkhead box P3; eBioscience, San Diego, CA) according to the manufacturer's instructions. In some experiments, cell proliferation was measured by staining with carboxyfluorescein succinimidyl ester (Invitrogen).
Plasma Analyses
The titers of specific antibodies to ApoB100 were measured by enzyme-linked immunosorbent assay as described previously. 5 Plasma cholesterol and triglycerides were measured with enzymatic colorimetric kits (Randox Laboratory Ltd, Crumlin, United Kingdom) according to the manufacturer's protocol.
Statistical Analysis
Values are expressed as meanϮSEM unless otherwise indicated. The nonparametric Mann-Whitney U test was used for pairwise comparisons and the Kruskal-Wallis test for multiple comparisons. Differences between groups were considered significant at PϽ0.05.
Results

Tolerogenic DCs Promote Regulatory T Cells and Have an Impaired Ability to Induce Effector T-Cell Responses
DCs were prepared from bone marrow of huB100 tg ϫLdlr Ϫ/Ϫ mice and maturated by lipopolysaccharide treatment in the presence or absence of IL-10. These DCs displayed a characteristic CD11c ϩ Flt3 Ϫ I-A b -positive phenotype with Ͼ90% CD11c ϩ cells (online-only Data Supplement Figure I ). IL-10 treatment of DCs did not affect the mean cell-surface expression of the costimulatory factors CD80 and CD86 or the coinhibitory molecules programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2; online-only Data Supplement Figure I ). Secretion of TNF-␣, monocyte chemotactic protein-1, and IL-12 from DCs was increased markedly after uptake of ApoB100 but was repressed significantly on concomitant treatment with IL-10 ( Figure 1 ).
To assess the functional activity of IL-10 -treated DCs, we added such cells to polyclonally activated spleen CD4 ϩ T cells. This led to significantly reduced IFN-␥ production and to modestly increased IL-10 production by these T cells ( Interleukin-10 (IL-10)-treated dendritic cells (DCs) inhibit T-cell proliferation and effector function but stimulate de novo generation of regulatory T cells (Treg). A total of 1ϫ10 4 CD11c ϩ DCs treated with or without IL-10 were coincubated for 96 hours with 4ϫ10 4 CD4 ϩ T cells purified from mouse spleen and activated with anti-CD3. A-C, Fluorescent-activated cell sorter data from a representative experiment that was performed twice with similar results. A, Intracellular staining of CD4 ϩ T cells after 96 hours of coincubation. Cells were restimulated with phorbol 12-myristate 13-acetate and ionomycin and added together with brefeldin A for the last 5 hours of culture. CD4 ϩ T cells were then stained with anti-interferon (IFN)-␥ and anti-IL-10 according to the manufacturer's protocol (BD Biosciences). B, Spleen CD4 ϩ T cells were depleted of CD25 ϩ natural Treg, stained with carboxyfluorescein succinimidyl ester (CFSE) to visualize cell proliferation, cocultured for 96 hours, and stained for FoxP3. Dot plots show CFSE staining reflecting the number of DNA replications on the x axis and staining for FoxP3, identifying FoxP3 ϩ Treg (top) and FoxP3 Ϫ effector T cells (bottom), on the y axis. C, Overlay histogram showing CFSE staining in FoxP3 Ϫ effector T cells cultured with DCs (shaded area) and DCs pretreated with IL-10 (black line), with peaks reflecting cell divisions (due to dilution of CFSE dye in each cell division, highly proliferating cells are toward the left and nonproliferating cells are toward the right). Max indicates maximum. D, 5ϫ10 4 cells of the T-cell hybridoma 48.5, which specifically recognizes apolipoprotein B100 (ApoB100), were coincubated with 2ϫ10 5 washed DCs that had been pretreated for 24 hours in the presence or absence of IL-10 and ApoB100, as indicated by (ϩ) or (Ϫ) in the graph. The DCs originated from donor mice expressing either I-A b or I-A d . T-cell activation was measured 24 hours later by interleukin-2 (IL-2) secretion. **PϽ0.01 vs DCϩApoB100 (nϭ4); ns indicates not significant. stimulator). The coinhibitory receptor PD-1, which is involved in T-cell inhibition, autoimmunity, and peripheral tolerance, 36 was slightly upregulated on T cells stimulated by IL-10 -treated DCs (online-only Data Supplement Figure II) .
Compared with nontreated DCs, exposure to IL-10 -treated DCs more than doubled the number of FoxP3 ϩ CD4 ϩ Treg cells among purified spleen CD4 ϩ T cells that had been depleted of preexisting CD25 ϩ Treg, which suggests de novo generation ( Figure 2B ; online-only Data Supplement Table I ).
IL-10 -treated DCs promoted significantly less effector T-cell proliferation on polyclonal stimulation than did regular myeloid DCs (Figures 2B and 2C ; online-only Data Supplement  Table II) .
We have found recently that atherogenic T cells recognize ApoB100-derived peptides of native LDL in an I-A b -restricted manner. 5 When DCs pulsed with ApoB100 and IL-10 were incubated with the ApoB100-specific T-cell hybridoma 48.5, they suppressed its activation compared with its re- sponse to DCs pulsed with ApoB100 in the absence of IL-10 ( Figure 2D ). When DCs from I-A d donors were used, or when antibodies against I-A b were added to the culture, the response was abrogated, which demonstrates that I-A b restricted antigen presentation of ApoB100 by DCs to T cells ( Figure 2D ; online-only Data Supplement Figure III) . Taken together, these data show that IL-10 treatment renders DCs tolerogenic, which leads to reduced T-cell activation in response to disease-specific antigen and polyclonal stimuli, increased induction of FoxP3 ϩ Treg, and reduced proinflammatory effector T-cell responses.
Tolerogenic DCs Presenting ApoB100 Reduce Atherosclerosis in Hypercholesterolemic Mice
HuB100 tg ϫLdlr Ϫ/Ϫ mice were used to test the effect of tolerogenic DCs on atherosclerosis. These mice express full-length human ApoB100 in the liver and display humanized hyperlipidemic lipoprotein profiles. The huB100 tg ϫLdlr Ϫ/Ϫ model permits the use of human ApoB100 as antigen. 5 Mice received a single intravenous injection of DCs that had been pulsed with either (1) decrease (Ϸ70%) in surface lesion area of the descending thoracic aorta was observed in mice that received ApoB100loaded tolerogenic DCs compared with all other groups that received DCs (Ϸ55% reduction compared with untreated mice; Figure 3 ). Immunohistochemical analysis of cryosections from the aortic root showed significantly reduced infiltration of CD4 ϩ T cells in atherosclerotic lesions of mice that received ApoB100-loaded tolerogenic DCs compared with mice that received DCs pulsed with ApoB100 alone ( Figure 4A ). Lesions of mice injected with ApoB100-loaded tolerogenic DCs displayed significantly increased amounts of collagen fibers compared with mice that received unloaded tolerogenic DCs ( Figure 4B ). No significant differences between treatment groups were registered by immunohistochemical analysis of CD8, CD11c, vascular cell adhesion molecule-1, and I-A b (online-only Data Supplement Figure IV) . Very few FoxP3 ϩ cells were detected in lesions of any of the groups (data not shown). Aortic FoxP3 mRNA levels did not differ between groups (online-only Data Supplement Figure V) . Body weight, plasma cholesterol, and triglyceride levels did not differ between groups (Table) .
ApoB100-Loaded Tolerogenic DCs Induce Antigen-Specific CD4 ؉ Treg Cells That Suppress T-Cell Effector Responses to ApoB100
To investigate the functional activity of Treg cells in the huB100 tg ϫLdlr Ϫ/Ϫ mice treated with tolerogenic DCs, we purified CD4 ϩ T cells from spleens of treated mice and tested whether they could suppress activation of a T-cell hybridoma that recognizes ApoB100 in an I-A b -restricted manner. CD4 ϩ T cells from mice injected with tolerogenic ApoB100pulsed DCs significantly suppressed activation of the ApoB100-specific T cells ( Figure 5A ). None of the CD4 ϩ T-cell populations from mice injected with DCs and treated with antigen or cytokine alone could suppress these ApoB100-specific T cells ( Figure 5A ).
ApoB100-Loaded Tolerogenic DCs Downregulate Proinflammatory T-Cell Responses in an Antigen-Dependent Manner and Mobilize Antiinflammatory Activity In Vivo
Splenocytes from huB100 tg ϫLdlr Ϫ/Ϫ mice proliferate in response to human ApoB100 and display a Th1 cytokine profile. 5 We transferred tolerogenic DCs to test whether this response can be suppressed in vivo. When recipients were injected subcutaneously with 100 g of ApoB100 1 week after injection of ApoB100-pulsed DCs, a vivid recall response was registered to the protein, with splenocytes secreting increased amounts of IFN-␥, TNF-␣, and IL-6 in response to ApoB100 ( Figure 5B ). However, spleens of mice injected with ApoB100-loaded tolerogenic DCs displayed significantly decreased production of IFN-␥, TNF-␣, and IL-6, as well as IL-5 ( Figure 5B ). This indicates that the tolerogenic treatment reduced antigen-specific responses in immunized mice.
mRNA levels for FoxP3, IL-10, and transforming growth factor-␤1 were increased and IL-12 was decreased in spleens of mice that received ApoB100-loaded tolerogenic DCs ( Figure 6 ). Transcripts for ICOS ligand, PD-1, and PD-L1 were increased after treatment with IL-10 -pulsed DCs irrespective of whether they were loaded with antigen (onlineonly Data Supplement Figure VI) . Lymph nodes of mice treated with tolerogenic DCs showed significantly lower levels of IL-12 and IL-5 and increased levels of ICOS ligand compared with mice that received DCs pulsed with ApoB100 alone (online-only Data Supplement Figure VI) . These data show that tolerogenic DCs induce a regulatory and antiinflammatory machinery in the lymphoid organs of treated mice.
The Atheroprotective Effect of Tolerogenic DCs Is Associated With Decreased Cellular But Not Humoral Immunity to ApoB100
Hypercholesterolemic mice injected with ApoB100-loaded tolerogenic DCs displayed significantly suppressed proliferative spleen T-cell responses to ApoB100 at 40 g/mL ( Figure 7A ). Plasma levels of IFN-␥ were also decreased significantly in these mice compared with mice that received ApoB100-loaded DCs ( Figure 7B ). IgG antibodies to ApoB100 were increased significantly in the 2 groups of mice that received DCs pulsed with ApoB100, irrespective of whether they were treated with IL-10 to become tolerogenic ( Figure 7C) . A similar trend was seen for IgG antibodies to oxidized LDL (data not shown). No significant differences were seen for IgM titers against ApoB100 in plasma of injected mice ( Figure 7D ). Therefore, the atheroprotective effect of ApoB100-loaded tolerogenic DCs is associated with inhibition of effector T-cell responses but not antibody production.
Discussion
The significant role of adaptive immunity in atherosclerosis is well established and makes it likely that antigen-presenting DCs are of importance for disease development. This was recently supported by studies that showed that transfer of LDL-loaded DCs into hypercholesterolemic mice accelerated atherosclerosis, 31 and that an extended lifespan of DCs affected plaque inflammation and cholesterol metabolism. 37 One may surmise that manipulation of DC activity could be used to reduce the autoimmune response to LDL components and ameliorate atherosclerosis. We now show that DCs can be made tolerogenic to LDL autoimmunity by treating them with IL-10 while loading them with ApoB100. Such ApoB100-loaded tolerogenic DCs inhibited the proliferative and proinflammatory T-cell response to ApoB100 and promoted the development of regulatory T cells. When injected into atherosclerosis-prone huB100 tg ϫLdlr Ϫ/Ϫ mice, they induced antiinflammatory activity, reduced immune cell infiltration into lesions, and mediated a significant reduction of atherosclerotic lesion size compared with immunogenic ApoB100-loaded DCs or vehicle controls.
The atheroprotective effect of ApoB100-loaded tolerogenic DCs was paralleled by reduced plasma levels of IFN-␥ and reduced CD4 ϩ T-cell infiltration into lesions but affected neither entry of CD11c ϩ DCs, expression of major histocompatibility complex class II (I-A) or vascular cell adhesion molecule-1 in lesions, nor plasma lipid levels. This suggests that activation and recruitment to lesions of effector T cells is of major importance for the atheroprotective effect of these tolerogenic DCs. Because FoxP3 ϩ Treg and the coinhibitory molecule PD-1 were increased in T-cell populations exposed to tolerogenic DCs and a significant inhibition of helper T-cell immunity was seen in mice injected with such DCs, the present data point to suppression of cell-mediated immune responses as a likely pathway. This is in line with previous studies showing inhibitory effects on effector T-cell immunity when Treg function was stimulated by IL-10 -treated tolerogenic DCs. 21, 26, 38 It has been suggested that the effects of such tolerogenic DCs are mediated by downregulation of costimulatory molecules, major histocompatibility complex class II, and IL-12. 21 We did not see any such difference in surface-marker expression; however, IL-12 expression was repressed in tolerogenic DCs and in lymphoid organs of mice injected with these DCs. IL-12 is one of the major determinants for differentiation of naïve T cells into effector Th1 cells, with ensuing production of IFN-␥. 39 This further supports the present data that the effect of tolerogenic DCs on atherosclerosis is mediated by suppression of effector T-cell immunity.
The notion that antigen-specific tolerogenic DCs operate through cell-mediated immunity when reducing atherosclerosis is also supported by the reduced T-cell proliferation to apoB100 in treated mice in the present study. In contrast, B-cell responses to ApoB100 were not affected significantly. This suggests that humoral immunity is less important than cellular immunity for the atheroprotective effect of tolerogenic DCs.
Several lines of evidence support a role for antigen specificity in atheroprotective immunity. Only tolerogenic DCs loaded with apoB100 antigen had a protective effect; the fact that just a single injection of such DCs was sufficient to achieve protection 10 weeks later points to a role for immunologic memory. Of note, DCs prepared in this way present not only the loaded antigen (in this case, apoB100) but also BSA, which is present in the medium needed for DC differentiation. 40 Presentation of BSA did not affect disease, because lesions of mice that received tolerogenic DCs without apoB100 did not differ from those of control mice that did not receive any DCs. Instead, atheroprotection was dependent on presentation of ApoB100 by tolerogenic DCs. We and others have previously shown that repeated immunization with antigen-loaded immunogenic DCs increases atherosclerosis. 31, 41 This effect was observed both when DCs were loaded with oxidized LDL 25 and when they were loaded with an artificial antigen expressed transgenically in the artery wall. 41 In contrast, it was reported recently that immunogenic DCs loaded with oxidized LDL reduced lesions induced when a collar was surgically attached to the carotid artery of hypercholesterolemic mice, whereas aortic lesions were unchanged. 42 The present study may shed light on these seemingly contradictory studies. When ApoB100-pulsed immunogenic DCs were administered, a modest, nonsignificant increase in lesion size was observed. Tolerogenic modulation of DCs by IL-10 treatment led to a significant reduction of lesions under otherwise similar conditions. Therefore, the local concentration of IL-10 and other mediators that influence DC phenotype could conceivably determine the outcome of DC transfer experiments. Because IL-10 expression increases with increasing plasma cholesterol levels, 43 the choice of hypercholesterolemic atherosclerosis model may also affect the balance between conventional and tolerogenic DCs. When these findings are translated into clinical use for humans, the immunologic properties of donor and recipient will also be of major importance, because only human leukocyte antigen-matched tolerogenic DCs are likely to confer atheroprotection.
Conclusions
We present here a novel treatment regimen for atherosclerotic disease. Using a tolerogenic DC therapy that targets immune reactions to the ApoB100 protein present in LDL, it was possible to attenuate systemic inflammation and reduce the atherosclerotic plaque burden by Ϸ70%. Because both LDL and markers of inflammation are major risk factors for coronary and cerebrovascular disease, and because current treatment benefits only a limited proportion of all those considered at risk, the present findings should encourage development of DC therapy as an additional approach to cardiovascular prevention and therapy.
